Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 7.7% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 7.7% during mid-day trading on Thursday . The stock traded as low as $0.38 and last traded at $0.40. 34,984,174 shares changed hands during trading, a decline of 67% from the average session volume of 104,525,602 shares. The stock had previously closed at $0.43.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Saturday, January 25th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The firm has a market cap of $70.08 million, a P/E ratio of -0.01 and a beta of 2.02. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average of $0.29 and a 200-day moving average of $0.28.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.